Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-64005 in adult ADHD
NCT03324581Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Nov 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of centanafadine in attention deficit hyperactivity disorder (ADHD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Nov 2017; status: completed.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03324581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03324581.